Global Dry Eye Disease Market

Dry Eye Disease Market Size, Share, Growth Analysis, By Product Type (Cyclosporine, Corticosteroids), By Formulation Type (Liquid, Gel), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region - Industry Forecast 2026-2033

Report ID: SQMIG35D2172 | Region: Global | Published Date: January, 2025
Pages: 157 |Tables: 65 |Figures: 75

To request a free sample copy of this report, please complete the form below.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt

    • FAQs

    Dry Eye Disease Market size was valued at USD 6.05 Billion in 2024 and is poised to grow from USD 6.54 Billion in 2025 to USD 12.2 Billion by 2033, growing at a CAGR of 8.1% during the forecast period (2026–2033).

    The market for dry eye disease is moderately competitive. In terms of market share, the market is currently dominated by a few major players. With the growing geriatric population and high disease prevalence, a few new smaller players are expected to enter the market in the coming years. AbbVie Inc. (Allergan PLC), Alcon Inc., and Santen Pharmaceutical Co. are among the market's major players. 'Novartis (Switzerland)', 'Allergan (Ireland) ', 'AbbVie (US) ', 'Johnson & Johnson (US) ', 'Bausch + Lomb (Canada) ', 'Rohto Pharmaceutical Co., Ltd. (Japan) ', 'Oculis (Switzerland) ', 'Visus Therapeutics (US) ', 'Kala Pharmaceuticals (US) ', 'Sun Pharmaceutical Industries Ltd. (India) ', 'Prestige Consumer Healthcare (US) ', 'Similasan Corporation (Switzerland) ', 'Scope Ophthalmics (UK) ', 'Thea Pharmaceuticals (France) ', 'Ursapharm Arzneimittel GmbH (Germany) ', 'EyeGate Pharmaceuticals, Inc. (US) ', 'Aldeyra Therapeutics (US) ', 'QuidelOrtho Corporation (US)'

    Dry eye disease, also known as keratoconjunctivitis sicca (KCS), is a common ophthalmic disorder that affects about 360 million people worldwide. Patients complain of dryness, irritation, redness, fatigue, and blurred vision. The prevalence varies with age, but it is increasing in both the young and old populations due to increased screen time, poor diet, increased use of contact lenses, and an increase in the number of LASIK surgeries. The ability of the lachrymal glands to produce tears decreases with age, resulting in dry eyes. One of the key factors contributing to the growth of the global dry eye drugs market is the rising incidence of dry eye disease due to an ageing population.

    One of the leading market trends in the dry eye disease market has been an increase in R&D spending, successful clinical trials, and increased new product approvals. A large number of companies are involved in clinical trials, such as Aldeyra Therapeutics, Inc.'s pipeline candidate Reproxalap, which is currently in Phase - III. This type of initiative is expected to drive the dry eye disease treatment market's revenue generation.

    The global dry eye disease market is studied on the basis of geography as North America, Europe, Asia-Pacific, South America, and Middle East & Africa. Due to the high prevalence of dry eye diseases and the ease with which solutions are available in the region, North America is expected to hold a significant share of the dry eye disease market. In this multi-screen world, people of all ages can be found. Computer or digital screen use may result in less blinking, which may contribute to symptoms of dry eye disease (DED), thereby increasing the demand for better and more effective DED therapeutics, which is expected to fuel growth in the North American region studied.

    Related Reports

    Dry Eye Syndrome Treatment Market
    Buy Now GET FREE SAMPLE
    Eye Health Ingredients Market
    Buy Now GET FREE SAMPLE
    Ophthalmic Disease Therapeutics Market
    Buy Now GET FREE SAMPLE
    Retinal Disorder Treatment Market
    Buy Now GET FREE SAMPLE
    Eye Health Supplements Market
    Buy Now GET FREE SAMPLE
    Diabetic Retinopathy Market
    Buy Now GET FREE SAMPLE
    Retinal Disease Therapeutics Market
    Buy Now GET FREE SAMPLE
    Eyewear Market
    Buy Now GET FREE SAMPLE

    Feedback From Our Clients

    Global Dry Eye Disease Market

    Report ID: SQMIG35D2172

    $5,300
    BUY NOW